Dravet Syndrome Treatment Market 2020 Top 10 Countries Exclusive Data, Demand, Share and Growth Analysis by Key Participant up to 2026

SEATTLE, March 25, 2021, (PHARMIWEB) — Global Dravet Syndrome Treatment Market

Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in the initial years of life and remains throughout the lifetime. Children suffering from the Dravet syndrome experience different types of seizures, namely, myoclonic seizures, tonic-clonic seizures, absence seizures, atypical absence seizures, atonic seizures, focal aware or impaired awareness seizures (previously called partial seizures), and status epilepticus. Generally, a combination of drugs is prescribed for the treatment of Dravet syndrome. Anticonvulsants, including stiripentol, topiramate, and Valproic acid, are the most commonly used drugs for treatment of this condition. In particular cases, where the intensity of the seizures are not reduced by medication, certain devices are used to do the same. For instance, vagal nerve stimulation device is one such device that delivers electrical impulses to the vagus nerve.

Request to view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1548

Global Dravet Syndrome Treatment Market Drivers

Increasing research & development activities for the development of novel drugs for Dravet syndrome, and subsequently their approval in key regions such as North America and Europe is expected to fuel growth of the global Dravet syndrome treatment market in near future. In 2017, Epygenix Therapeutics, Inc.—a biopharmaceutical company—received U.S. Food and Drug Administration (FDA) orphan drug designation for its EPX-300, indicated for the treatment of Dravet syndrome. In 2017, Ovid Therapeutics—a U.S.-based biopharmaceutical company—received orphan drug designation for TAK-935/OV935 by U.S. Food and Drug Administration (FDA). In February 2018, Zogenix Inc. announced FDA approval of breakthrough therapy designation to ZX-008, its Phase III drug for seizures associated with Dravet Syndrome. In 2017, OPKO Pharmaceuticals LLC, a subsidiary of OPKO Health, Inc., received orphan drug designation from U.S. FDA for its oligonucleotide-based AntagoNAT (CUR-1916) indicated for the treatment of Dravet Syndrome, and the company also received orphan drug designation for its CUR-1916 from European Commission during the same year. Furthermore, strategic collaborations among the key players in market for the development and manufacturing of drugs indicated for treatment of Dravet syndrome is also expected to drive growth of the Dravet syndrome treatment market. For instance, in 2017, Laurus Synthesis Inc. and Epygenix Therapeutics, Inc., entered into a strategic collaboration for the development and manufacture of EPX-100. As part of the agreement, Laurus Synthesis provides chemistry development services in support of an upcoming clinical trial for EPX-100, which is intended for adolescents suffering from Dravet syndrome. Furthermore, in 2017, Takeda Pharmaceutical Company Limited entered into a global collaboration agreement with Ovid for development and commercialization of TAK-935/OV935 for the treatment of developmental and epileptic encephalopathies.

Exclusive offer!!! Purchase the report at a discounted rate!!!

Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount

Quick Buy – Dravet Syndrome Treatment Market Research Report: https://bit.ly/3tKYeFk

Global Dravet Syndrome Treatment Market – Regional Analysis

North America is expected to a hold dominant position in the global Dravet syndrome treatment market, owing to increasing initiatives and funding by various organizations to support the development of new treatment for Dravet syndrome. For instances, in 2017, The Dravet Syndrome Foundation, a U.S.-based non-profit organization dedicated to funding the highest caliber research on Dravet syndrome, funded a total amount of US$ 3,600,000 for the development of novel treatment methods for Dravet syndrome. In 2011, Dravet Syndrome Foundation granted an undisclosed amount to U.S.-based OPKO Health, Inc., to support the company’s efforts to develop potential therapeutic agents for the treatment of Dravet syndrome. The market in Europe is expected to exhibit significant growth in the Dravet syndrome treatment market, owing to increasing research and development activities being adopted by key players present in the region. For instance, GW Pharmaceuticals, a British biopharmaceutical company, developed Epidiolex (cannabidiol) based on an ingredient derived from marijuana. The company submitted a new drug application (NDA) to the U.S. FDA for Epidiolex, in December 2017.

Global Dravet Syndrome Treatment Market – Competitive Scenario

The leading players operating in the global Dravet syndrome treatment market include Epygenix Therapeutics, Inc., Ovid Therapeutics, GW Pharmaceuticals Plc., Takeda Pharmaceutical Company Ltd, Zogenix, Inc., OPKO Health Inc., Biocodex S.A., Biscayne Neurotherapeutics, Inc., and PTC Therapeutics, Inc. These companies are said to be striving to receive approval for their novel drugs from major regulatory bodies, such as the FDA and the European Commission. For instance, in 2017, Biscayne Neurotherapeutics, Inc., received an Orphan Drug designation from the U.S. FDA for its compound BIS-001 indicated for the treatment of Dravet syndrome.

*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1548

Global Dravet Syndrome Treatment Market Taxonomy

By Treatment Type,

• Drugs
  • Anticonvulsant
  • Benzodiazepines
  • Others
• Device
  • Vagal Nerve Stimulation

By Distribution Channel,

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region,

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837